Case Study Sanctura. (trospium chloride)
|
|
- Reginald Ellis
- 8 years ago
- Views:
Transcription
1 Case Study Sanctura (trospium chloride)
2 Bad Ad Case Study Sanctura (trospium chloride) Facilitator Guide Approximate Time: 30 minutes Exercise prerequisite: Students should view the Bad Ad e-learning CME/CE course located on CD- ROM or at prior to completing this exercise. Student Materials: Before the exercise: Sanctura journal advertisement Prescribing Information (PI) for Sanctura After the exercise: Sanctura journal advertisement (journal ad), keyed with answers FDA untitled letter for Sanctura Student evaluation form Facilitator Materials: Facilitator guide (includes a detailed answer key for the case study) Facilitator instructions: 1. Distribute the Sanctura journal ad along with the PI for Sanctura. 2. Present the Background and Case Study Instructions shown below. 3. Allow students approximately 10 minutes to review the Sanctura journal ad. 4. Use the discussion questions in this guide to assist students in identifying prescription drug promotion regulatory issues of concern, including false or misleading statements. 5. After discussing the regulatory issues of concern, distribute the Sanctura journal ad, keyed with answers, along with the FDA untitled letter for Sanctura. 2
3 Background and case study instructions: This promotional piece is a health care professional journal advertisement for Sanctura. Sanctura is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Using the PI as a reference, identify the issues of concern in the advertisement. (Approximately 10 minutes) Discussion Questions: General 1. What are the key promotional messages for Sanctura in the journal ad? 2. Based on your knowledge and information from the PI, which claims, if any, do you think are false or misleading? Specific 3. Is there evidence to support the following claims in the journal ad? a. In a world where many OAB drugs are the same... ONE stands out. (page 1) b. SANCTURA stands alone. The unique quaternary structure makes all the difference. (page 2) (See Detailed Answer Key #1 Unsubstantiated Superiority) 4. Does the journal ad adequately communicate adverse events and other risks associated with Sanctura? (See Detailed Answer Key #2 Omission and Minimization of Risk) 5. Is there evidence to support the following claims made on page 2 of the journal ad? a. No known metabolic drug interactions b. A safe choice (See Detailed Answer Key #2 Omission and Minimization of Risk) 6. Is there evidence to support the following claims made on page 2 of the journal ad? a. Day 1 relief with sustained efficacy. b. Quality of life significantly improved. (See Detailed Answer Key #3 Overstatement of Efficacy) 3
4 Detailed Answer Key: 1. Unsubstantiated Superiority The journal ad includes the claim In a world where many OAB drugs are the same... ONE stands out coupled with the illustration of a large four-leaf clover surrounded by a golden halo, standing above numerous three-leaf clovers. This claim and presentation misleadingly suggests that Sanctura confers more therapeutic benefits than other therapies for OAB when this has not been demonstrated by substantial evidence or substantial clinical experience. The journal ad claims SANCTURA stands alone. The unique quaternary structure makes all the difference. This claim suggests that Sanctura is superior to other OAB therapies based on its clinical pharmacology. Although the intrinsic chemical structure (i.e., quaternary amine) of Sanctura is different from other OAB drugs, FDA was not aware of any studies demonstrating that the structure of Sanctura offered any distinct patient benefits or conveyed any clinically significant advantage, nor was FDA aware of any studies indicating that Sanctura was superior to other drugs for the treatment of OAB Omission and Minimization of Risk The journal ad fails to present risk information with a prominence and readability reasonably comparable to the presentation of efficacy claims for Sanctura. Throughout the journal ad, effectiveness claims are presented using large, bold, colorful text and graphics. In contrast, the risk information is presented at the bottom of the first page of the journal ad in a single block paragraph, in small black font, following a statement of the indication without any signal to indicate to the reader that this is important risk information. The journal ad includes the claim No known metabolic drug interactions. This claim is misleading because although it presents positive information concerning certain drug-drug interactions, it omits risk information associated with the concomitant use of Sanctura and other drugs. Although metabolic drug interactions between Sanctura and other medications are not expected, as stated in the PRECAUTIONS section of the PI, Sanctura is associated with risks related to drug interactions with other anticholinergic agents. The PI also recommends careful patient monitoring for patients receiving Sanctura concomitantly with drugs 1 When FDA reviews a promotional piece, it makes such judgments in light of the information available at that time. 4
5 eliminated by active tubular secretion (e.g., procainamide, pancuronium, morphine, vancomycin, metformin, and tenofovir). By not disclosing this risk information, the journal ad misleadingly suggests that Sanctura is safer than has been demonstrated. The journal ad fails to communicate pertinent risks such as common adverse events associated with Sanctura (e.g., dry mouth, constipation, and headache). By omitting these risks, the journal ad misleadingly suggests that Sanctura is safer than has been demonstrated. The omission of these risks is exacerbated by the claim in the ad that Sanctura is A safe choice, which further minimizes the risks associated with the use of Sanctura. 2. Overstatement of Efficacy The journal ad includes the claim Day 1 relief... This claim is misleading because it is not supported by substantial evidence or substantial clinical experience. The reference cited for this claim is a post-hoc analysis of efficacy data from one of the clinical studies (described in the CLINICAL STUDIES section of the PI) in which patients with overactive bladder were randomized to placebo or Sanctura. Although the approach used could potentially be acceptable if planned prospectively, the analysis of the data in this case was done retrospectively. This retrospective analysis does not soundly support the claim made. The journal ad claims Quality of life significantly improved This claim is misleading because it asserts that Sanctura significantly improves a patient s quality of life when this has not been demonstrated by substantial evidence or substantial clinical experience. In support of this claim, the journal ad references a study that is not adequately designed to support the claim. Among the reasons that this study is insufficient, the instrument used in the referenced study was the Incontinence Impact Questionnaire (IIQ), which measures the impact of overactive bladder on travel, physical activity, social relationships, and emotional health but not on other domains covered by the broad claim of quality of life such as non-healthrelated aspects of life including work productivity and financial stability. The referenced study also did not show a significant improvement on all of the IIQ subscales; specifically, the results demonstrated that Sanctura did not affect the physical activity subscale that reflects the impact of incontinence on patient perception of overall physical health, shopping activities, and ability to perform household chores. Moreover, the IIQ used in this study was not validated in men, and the IIQ scores in men did not improve in this study. Therefore, this reference cannot support the claim in the Ad that Sanctura will significantly improve patients' quality of life. 5
6 Outcome: The FDA untitled letter for Sanctura was issued on January 27, As a result, the manufacturer for Sanctura stopped using the journal ad. In addition, the manufacturer for Sanctura stopped using other promotional pieces for Sanctura that contained similar claims and presentations. 6
Overactive Bladder New Antimuscarinics for Treatment
Urology Overactive Bladder New Antimuscarinics for Treatment a report by Karl-Erik Andersson, MD, PhD Professor and Chairman, Department of Clinical Pharmacology, University of Lund, Sweden Summary Antimuscarinics
More informationCarol Childers Director Teva Neuroscience, Inc. 901 East 104 th Street, Suite 900 Kansas City, MO 64131. RE: ANDA 076809 Clozapine tablets USP MA# 44
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 Carol Childers Director Teva Neuroscience, Inc. 901 East 104 th Street, Suite 900 Kansas
More informationPrescribing Pathway for Drug Treatment for Overactive Bladder.
East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG - Prescribing Clinical Network
More informationRE: NDA: 021876 DICLEGIS (doxylamine succinate and pyridoxine hydrochloride) delayed-release tablets, for oral use MA # 350 WARNING LETTER
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Eric Gervais, Executive Vice President 919 Conestoga Road Building
More informationOAB (Overactive Bladder)
OAB (Overactive Bladder) PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This webcast has been supported by an educational grant
More informationMedia Analysis of the Overactive Bladder Market
Media Analysis of the Overactive Bladder Market May 2001 September 2004 Prepared for: Watson Pharma, Inc. Background & Objectives This document summarizes media coverage related to overactive bladder,
More informationE-ALERT Food & Drug 2012 END-OF-YEAR SUMMARY OF FDA PROMOTIONAL ENFORCEMENT ACTIVITY OFFICE OF PRESCRIPTION DRUG PROMOTION (OPDP) ENFORCEMENT ACTIVITY
E-ALERT Food & Drug March 18, 2013 2012 END-OF-YEAR SUMMARY OF FDA PROMOTIONAL ENFORCEMENT ACTIVITY This client alert reviews the warning and untitled letters issued in 2012 by the Office of Prescription
More informationWARNING LETTER DEPARTMENT OF HEALTH & HUMAN SERVICES TRANSMITTED BY FACSIMILE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Peter A. Lankau President and CEO 100 Endo Boulevard Chadds Ford, PA
More informationPrimary Care management of Overactive Bladder (OAB)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Primary Care management of Overactive Bladder (OAB) Prescribing Tips All medicines for OAB have similar dose-related efficacy. More than one agent (up
More informationRegulation of Prescription Drug Promotion
Regulation of Prescription Drug Promotion Amy Toscano, Pharm.D., RAC, CPA Team Leader Office of Prescription Drug Promotion Food and Drug Administration June 2013 Overview Office of Prescription Drug Promotion
More informationWALKING THE COMPLIANCE LINE: A REGULATORY LAWYER S PERSPECTIVE
WALKING THE COMPLIANCE LINE: A REGULATORY LAWYER S PERSPECTIVE Presented By: Alan B. Minsk Partner and Chair, Food and Drug Practice Team Arnall Golden Gregory LLP alan.minsk@agg.com Presented To: ISMPP
More informationOVERACTIVE BLADDER DIAGNOSIS AND TREATMENT OF OVERACTIVE BLADDER IN ADULTS:
2014 OVERACTIVE BLADDER DIAGNOSIS AND TREATMENT OF OVERACTIVE BLADDER IN ADULTS: AUA/SUFU Guideline (2012); Amended (2014) For Primary Care Providers OVERACTIVE BLADDER Diagnosis and Treatment of Overactive
More informationApril 12, 2013 Mandy C. Leonard, Pharm.D., BCPS Department of Pharmacy
April 12, 2013 Mandy C. Leonard, Pharm.D., BCPS Department of Pharmacy Describe when medications are used for urinary incontinence (UI) Review medications used in UI including mechanism of action, key
More informationA review of antimuscarinic prescribing for urinary incontinence in primary care
A review of antimuscarinic prescribing for urinary incontinence in primary care Seema Gadhia On behalf of NHS Buckinghamshire Medicines Management Team In Collaboration with Introduction Urinary incontinence
More informationURINARY INCONTINENCE
URINARY INCONTINENCE What is urinary incontinence? Urinary incontinence is the uncontrollable loss of urine. The amount of urine leaked can vary from only a few drops when you cough or sneeze to entirely
More informationLearn More About Product Labeling
Learn More About Product Labeling Product label The product label is developed during the formal process of review and approval by regulatory agencies of any medicine or medical product. There are specific
More informationMedication for Overactive Bladder
Saint Mary s Hospital Gynaecology Service Warrell Unit Medication for Overactive Bladder Information for Patients What medication is available for overactive bladder? There are two types of medication
More informationSuffolk PCT Drug & Therapeutics Committee New Medicine Report
Suffolk PCT Drug & Therapeutics Committee New Medicine Report This drug has been reviewed because it is a product that may be prescribed in primary care. Medicine Fesoterodine (Toviaz, Pfizer) Document
More informationRegulatory Affairs Professionals Society: Regulatory Affairs Certification (RAC) Study Group FDA Regulation of Advertising and Promotion
Regulatory Affairs Professionals Society: Regulatory Affairs Certification (RAC) Study Group FDA Regulation of Advertising and Promotion Alex Toy July 14, 2013 1 Agenda FDA Regulatory Framework Office
More informationCONSENT FORM 12/19/08
12/19/08 1001 University Place Evanston, Illinois 60201 www.northshore.org CONSENT FORM Phone (224) 364-7100 Fax (847) 570-8011 Intravesical Alkalized Lidocaine for the Treatment of Overactive Bladder
More informationWARNING LETTER. Angus Russell Chief Executive Officer Shire Development Inc. 725 Chesterbrook Blvd. Wayne, PA 19087-5637
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Angus Russell Chief Executive Officer Shire Development Inc. 725 Chesterbrook
More informationSCENARIO SILK (naturneum ethyl ester) topical cream is the most recently (June 30, 2013) approved topical treatment for acne vulgaris.
SCENARIO (naturneum ethyl ester) topical cream is the most recently (June 30, 2013) approved topical treatment for acne vulgaris. It is approved to be used every other day. Two Phase III studies were done
More informationIntroduction to Compliance with FDA Labeling and Advertising Requirements
Introduction to Compliance with FDA Labeling and Advertising Requirements Second Annual Pharmaceutical Industry Regulatory and Compliance Summit Dick Kenny FDA History Basic function of government Oldest
More informationA Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
european urology 54 (2008) 740 764 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Neuro-urology A Systematic Review and Meta-Analysis of Randomized Controlled Trials
More informationNon-surgical Treatments for Urinary Incontinence. A Review of the Research for Women
Non-surgical Treatments for Urinary Incontinence A Review of the Research for Women Is This Information Right for Me? Yes, if: You are a woman who is older than 18. You are having trouble holding your
More informationHow To Weigh Data From A Study
PRINCIPLES ON RESPONSIBLE SHARING OF TRUTHFUL AND NON-MISLEADING INFORMATION ABOUT MEDICINES WITH HEALTH CARE PROFESSIONALS AND PAYERS INTRODUCTION In the era of data-driven medicine, where all parties
More informationFemale Urinary Incontinence
Female Urinary Incontinence Molly Heublein, MD Assistant Professor Clinical Medicine UCSF Women s Health Primary Care Disclosures I have nothing to disclose. 1 Objectives Review the problem Feel confident
More informationIncontinence. What is incontinence?
Incontinence What is incontinence? Broadly speaking, the medical term incontinence refers to any involuntary release of bodily fluids, but many people associate it strongly with the inability to control
More informationLincolnshire Knowledge and Resource Service
Lincolnshire Knowledge and Resource Service This search summary contains the results of a literature search undertaken by the Lincolnshire Knowledge and Resource Service librarians in; January 2012 All
More informationPOLICY STATEMENT. Guidelines for Refractive Surgery Advertising
POLICY STATEMENT Guidelines for Refractive Surgery Advertising A joint statement of the American Academy of Ophthalmology, the American Society of Cataract and Refractive Surgery and the International
More informationWARNING LETTER. Ian C. Reed Chairman and Chief Executive Officer Pfizer Inc. 235 East 42 nd Street New York, NY 10017
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 Ian C. Reed Chairman and Chief Executive Officer 235 East 42 nd Street New York, NY 10017
More informationTreatments for Overactive Bladder
Treatments for Overactive Bladder Patient Information Author ID: SA Leaflet Number: Gyn 051 Name of Leaflet: Treatments for overactive bladder Date Produced: October 2014 Review Date: October 2016 Treatment
More informationComparison of Fesoterodine, Tolterodine, Oxybutynin and Solifenacin in patients with overactive bladder A systematic review
Comparison of Fesoterodine, Tolterodine, Oxybutynin and Solifenacin in patients with overactive bladder A systematic review Hamed Kakarª, Bastiaantje M. Kok b, Sahar Mokhles c, Malalay Sarwar d * Supervisors:
More informationFadwa Almanakly, Pharm.D. Associate Director, Advertising and Promotions Bayer HealthCare Pharmaceuticals Inc. 6 West Belt Wayne, NJ 07470-6806
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Fadwa Almanakly, Pharm.D. Associate Director, Advertising and Promotions
More informationLondon New Drugs Group APC/DTC Briefing Document Mirabegron (Betmiga TM ) for overactive bladder March 2013
London New Drugs Group APC/DTC Briefing Document Mirabegron (Betmiga TM ) for overactive bladder March 2013 Summary Mirabegron is first of a new class of drug, beta-3-adrenoceptor agonists, for the treatment
More informationUrinary Incontinence FAQ Sheet
Urinary Incontinence FAQ Sheet Are you reluctant to talk to your doctor about your bladder control problem? Don t be. There is help. Loss of bladder control is called urinary incontinence. It can happen
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 18 December 2002 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE
More informationOveractive bladder syndrome (OAB)
Overactive bladder syndrome (OAB) Exceptional healthcare, personally delivered What is OAB? An overactive bladder or OAB is where a person regularly gets a sudden and compelling need or desire to pass
More informationGuidance for Industry
Guidance for Industry Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationGuidance on adverse drug reactions
Guidance on adverse drug reactions Classification of adverse drug reactions Adverse drug reactions are frequently classified as type A and type B reactions. An extended version of this classification system
More informationUniversity of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol
University of Hawai i Human Studies Program Guidelines for Developing a Clinical Research Protocol Following are guidelines for writing a clinical research protocol for submission to the University of
More informationTHE 7:16 WAS ON TIME BUT MY LEGS WERE BEHIND SCHEDULE THAT S WHEN I ASKED FOR THE WALKING PILL
THE 7:16 WAS ON TIME BUT MY LEGS WERE BEHIND SCHEDULE THAT S WHEN I ASKED FOR THE WALKING PILL See page 12 for FREE* TRIAL OFFER *Limitations and restrictions apply. Actor portrayal AMPYRA (dalfampridine)
More informationFINANCIAL SERVICES BOARD
Ref: Information Letter [-]/[-] (LT&ST) FINANCIAL SERVICES BOARD REPUBLIC OF SOUTH AFRICA LONG-TERM INSURANCE ACT, 1998 (ACT 52 OF 1998) SHORT-TERM INSURANCE ACT, 1998 (ACT 53 OF 1998) Addressee: Long-term
More informationFrustrated with your Overactive Bladder (OAB) medication not working? Can t handle the side effects?
Frustrated with your Overactive Bladder (OAB) medication not working? Can t handle the side effects? BOTOX treats adults with the OAB symptoms of leaking, going too often, and the strong sudden need to
More informationWARNING LETTER. According to its approved product labeling (PI) (in pertinent part, emphasis original):
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993-0002 TRANSMITTED BY FACSIMILE Sapan A. Shah, Ph.D. President and Chief Executive Officer
More informationThe Efficacy of the Antimuscarinic Drug Oxybutynin in the Treatment Women with Overactive Bladder (OAB) Symptoms
THE OVERACTIVE IRAQI POSTGRADUATE BLADDER MEDICAL JOURNAL The Efficacy of the Antimuscarinic Drug Oxybutynin in the Treatment Women with Overactive Bladder (OAB) Symptoms Jassim Mohammad Alkhazraji*, Ban
More informationGuidance for Industry
Guidance for Industry Consumer-Directed Broadcast Advertisements Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
More informationSOGC Recommendations for Urinary Incontinence
The quality of evidence is rated, and recommendations are made using the criteria described by the Canadian Task Force on Preventive Health Care. Clinical Practice Guidelines: The Evaluation of Stress
More informationmirabegron 25mg and 50mg prolonged-release tablets (Betmiga ) SMC No. (862/13) Astellas Pharma Ltd
mirabegron 25mg and 50mg prolonged-release tablets (Betmiga ) SMC No. (862/13) Astellas Pharma Ltd 05 April 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationSativex. Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353
Sativex Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Sativex Date of issue: July 2010 Review date: July 2011 Contents 1. Introduction 1 2. What is Sativex?
More informationSubject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
More informationNo-Action Letters. Administrative Proceedings
Performance Advertising Reconciling the GIPS Standards with the Investment Advisers Act of 1940 United States Investment Performance Committee (USIPC) Introduction This white paper addresses key differences
More informationFecal incontinence (Encopresis) It is the fecal incontinence condition observed in children with chronic constipation over 1-2 years.
WHAT IS DYSFUNCTIONAL URINATION (URINATION FUNCTION DISORDER)? It stands for the urination phase disorders, which appear due to wrongly acquired urination habits during the toilet training of some neurologically
More informationFair Balance on the Internet: A Review of Recent DDMAC Enforcement Action. By Alyson Sous, PharmD
Fair Balance on the Internet: A Review of Recent DDMAC Enforcement Action By Alyson Sous, PharmD 28 The Internet presents drug manufacturers and distributors with a significant opportunity to communicate
More informationThe overactive bladder and bladder retraining
Oxford University Hospitals NHS Trust The overactive bladder and bladder retraining Information for patients Normal bladder function Your bladder normally stores urine produced by your kidneys. The kidneys
More informationTABLE OF CONTENTS CHAPTER 9 PATIENT COUNSELING AND PROSPECTIVE DRUG USE REVIEW REGULATIONS
TABLE OF CONTENTS CHAPTER 9 PATIENT COUNSELING AND PROSPECTIVE DRUG USE REVIEW REGULATIONS Section 1. Authority 9-1 Section 2. Definitions 9-1 Section 3. Patient Profile Records 9-1 Section 4. Prospective
More informationQuestion ID: 6 Question type: Intervention Question: Does treatment of overactive bladder symptoms prevent falls in the elderly?
PRIORITY BRIEFING The purpose of this briefing paper is to aid Stakeholders in prioritising topics to be taken further by PenCLAHRC as the basis for a specific evaluation or implementation projects. QUESTION
More informationGuidance for Industry and FDA Staff
Guidance for Industry and FDA Staff Dear Health Care Provider Letters: Improving Communication of Important Safety Information U.S. Department of Health and Human Services Food and Drug Administration
More informationManaging Changes in Your Bladder Function After Cancer Treatment
Managing Changes in Your Bladder Function After Cancer Treatment Information for cancer survivors UHN Read this resource to learn: What a urinary problem is What causes it What you can do to improve your
More informationCommunicating uncertainty about benefits and
Communicating uncertainty about benefits and harms of pharmaceutical products Lisa M. Schwartz, MD, MS Steven Woloshin, MD, MS The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth
More informationKELLI DEWITT WHITEHEAD, RN, MS, ARNP
CIRRICULUM VITAE KELLI DEWITT WHITEHEAD, RN, MS, ARNP Associated Urologist, PA 341 Wheatfield, Suite 180 Sunnyvale, TX 75182 972-270-8859 EDUCATION Master of Science, Family Nurse Practitioner University
More informationTIBIAL NERVE STIMULATION: ONE OF SEVERAL NEW OPTIONS FOR THE MANAGEMENT OF OVERACTIVE BLADDER IN WOMEN
TIBIAL NERVE STIMULATION: ONE OF SEVERAL NEW OPTIONS FOR THE MANAGEMENT OF OVERACTIVE BLADDER IN WOMEN Scott A Farrell MD Professor Dept of Obstetrics and Gynaecology Dalhousie University Declaration of
More informationShared Care Protocol for the Prescription of Memantine for Alzheimer s disease
Shared Care Protocol for the Prescription of Memantine for Alzheimer s disease 1. REFERRAL CRITERIA Patients of any age that are suspected to be suffering from moderate to severe Alzheimer s disease will
More informationOveractive Bladder (OAB)
Overactive Bladder (OAB) Overactive bladder is a problem with bladder storage function that causes a sudden urge to urinate. The urge may be difficult to suppress, and overactive bladder can lead to the
More informationDrugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author
Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further
More informationEmergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
More informationTAKING THE NEXT STEP
FOR ADULTS WITH MS TAKING THE NEXT STEP AMPYRA TREATMENT GUIDE walking better matters See the Patient Medication Guide below. About AMPYRA (dalfampridine) Extended release tablets How is AMPYRA different?
More informationBJUI. A review of adherence to drug therapy in patients with overactive bladder
2008 BJU International. No claim to original US government works Mini-review Article ADHERENCE TO DRUG THERAPY IN PATIENTS WITH OAB BASRA et al. BJUI BJU INTERNATIONAL A review of adherence to drug therapy
More informationPROCEDURE FOR THE ASSESSMENT OF ADULTS AND CHILDREN WITH BLADDER OR BOWEL DYSFUNCTION
PROCEDURE FOR THE ASSESSMENT OF ADULTS AND CHILDREN WITH BLADDER OR BOWEL DYSFUNCTION First Issued Issue Version One Purpose of Issue/Description of Change Planned Review Date Procedure for the effective
More informationGuidance for Industry
Guidance for Industry Labeling for Human Prescription Drug and Biological Products Implementing the PLR Content and Format Requirements U.S. Department of Health and Human Services Food and Drug Administration
More informationOveractive Bladder Syndrome (OAB): Guidelines for prescribing. (CLINICAL GUIDELINE NO.)
Overactive Bladder Syndrome (OAB): Guidelines for prescribing. (CLINICAL GUIDELINE NO.) Document Reference Number: Ratified By: Ratified: (s) Reviewed: Next Review : Responsibility for Review: Contributors:
More informationGood Review Practice. October 2009 Labeling
Guidance for Industry and Review Staff Labeling for Human Prescription Drug and Biological Products Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information Good
More informationMarketing Through the Mail Checklist
Marketing Through the Mail Checklist Staying in contact with customers and prospects helps generate new business and new customers. Using the postal system can be an effective way to make those contacts
More informationEvaluating Prescription Drugs Used to Treat: Overactive Bladder. Comparing Effectiveness, Safety, and Price
Evaluating Prescription Drugs Used to Treat: Overactive Bladder Comparing Effectiveness, Safety, and Price Our Recommendations The six prescription drugs used to treat the urination disorder, overactive
More informationInterplay Between FDA Advertising and Promotion Enforcement Activities, Product Liability, and Consumer Fraud Litigation
Interplay Between FDA Advertising and Promotion Enforcement Activities, Product Liability, and Consumer Fraud Litigation Leslie M. Tector Quarles & Brady LLP September 30, 2014 Objectives Which federal
More informationOveractive Bladder (OAB) Content of the lecture
Overactive bladder (OAB) : Introduction and Medical Management R.J. Opsomer Cliniques St Luc, labo d urodynamique, UCL - Bruxelles Overactive Bladder (OAB) Content of the lecture The syndrome of Overactive
More informationMirabegron for treating symptoms of overactive bladder
Mirabegron for treating symptoms of overactive Issued: June 2013 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce technology
More informationThe Product Review Life Cycle A Brief Overview
Stat & Quant Mthds Pharm Reg (Spring 2, 2014) Lecture 2,Week 1 1 The review process developed over a 40 year period and has been influenced by 5 Prescription User Fee Act renewals Time frames for review
More informationWEBER STATE UNIVERSITY SPORTS MEDICINE INTERCOLLEGIATE ATHLETICS DRUG ABUSE PROGRAM
WEBER STATE UNIVERSITY SPORTS MEDICINE INTERCOLLEGIATE ATHLETICS DRUG ABUSE PROGRAM The department of intercollegiate athletics at Weber State University its coaching personnel and administrators, strongly
More informationXXXXX Petitioner File No. 115016-001 v. Issued and entered this 28 th day of April 2011 by R. Kevin Clinton Commissioner ORDER
STATE OF MICHIGAN DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS OFFICE OF FINANCIAL AND INSURANCE REGULATION Before the Commissioner of Financial and Insurance Regulation In the matter of XXXXX Petitioner
More informationOVERACTIVE BLADDER SYNDROME (OAB)
OVERACTIVE BLADDER SYNDROME (OAB) BLADDER ANATOMY AND FUNCTION The bladder is hollow balloon-shaped muscle that acts as a storage organ, holding urine from your kidneys until a convenient time for you
More informationU.S. Scientific Update Aricept 23 mg Tablets. Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc.
U.S. Scientific Update Aricept 23 mg Tablets Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc. Unmet Need in Moderate to Severe Alzheimer s Disease (AD) Ongoing clinical deterioration
More informationPerspectives on Patient Recruitment
Webcast Perspectives on Patient Recruitment Sponsors: Presenters Moderator: Christiane Truelove Editor in Chief, R&D Directions Chris.Truelove@ubm.com Speakers: Dr. Bradley Vince, D.O., President and Medical
More information6. MEASURING EFFECTS OVERVIEW CHOOSE APPROPRIATE METRICS
45 6. MEASURING EFFECTS OVERVIEW In Section 4, we provided an overview of how to select metrics for monitoring implementation progress. This section provides additional detail on metric selection and offers
More informationManagement of refractory OAB conditions
Management of refractory OAB conditions Neurotoxins and Neuromodulation Gary E. Lemack, M.D. Professor of Urology and Neurology Program Director in Urology UT-Southwestern Medical Center Overactive bladder
More informationWomen suffer in silence
Women suffer in silence Stress urinary incontinence is the involuntary loss of urine resulting from increased intra-abdominal pressure. In people who suffer with this condition, forms of exertion such
More informationI ve Got a Secret Identifying and Treating Urinary Incontinence in the Elderly
Page 1 I ve Got a Secret Identifying and Treating Urinary Incontinence in the Elderly Identifying and Treating Urinary Incontinence in the Elderly Wanda C. Hancock, MHSA, PA-C Supported by an educational
More informationRole of the Investigational Drug Services (IDS) in the Management of Investigational Drugs
Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs Charlesworth Rae, BS, PharmD, JD Investigational Drug Pharmacist July 2012 1 Outline of Presentation I. Introduction
More informationTest Content Outline Effective Date: June 9, 2014. Pain Management Nursing Board Certification Examination
Pain Management Nursing Board Certification Examination There are 175 questions on this examination. Of these, 150 are scored questions and 25 are pretest questions that are not scored. Pretest questions
More informationLEGISLATURE OF THE STATE OF IDAHO Sixtieth Legislature First Regular Session 2009 IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO.
LEGISLATURE OF THE STATE OF IDAHO Sixtieth Legislature First Regular Session 0 IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO. BY BUSINESS COMMITTEE 0 AN ACT RELATING TO HEALTH INSURANCE; AMENDING TITLE,
More informationP3 / PERSONAL ASPECTS. Drugs
P1 / DRUGS An addiction treatment facility such as Delray Recovery Center often treats patients who are addicted to more than one drug. P2 / SUBSTANCES Learn about Alcohol and Amphetamines, including the
More informationUltram (tramadol), Ultram ER (tramadol extended-release tablets); Conzip (tramadol extended-release capsules), Ultracet (tramadol / acetaminophen)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.35 Subject: Tramadol Acetaminophen Page: 1 of 8 Last Review Date: September 18, 2015 Tramadol Acetaminophen
More informationA Phase 2 Study of HTX-011 in the Management of Post-Operative Pain Positive Top-Line Results
A Phase 2 Study of HTX-011 in the Management of Post-Operative Pain Positive Top-Line Results September 22, 2015 Forward-Looking Statements This presentation contains "forward-looking statements" as defined
More informationPrimary Care Management of Male Lower Urinary Tract Symptoms. Matthew B.K. Shaw Consultant Urological Surgeon
Primary Care Management of Male Lower Urinary Tract Symptoms Matthew B.K. Shaw Consultant Urological Surgeon NICE LUTS Guidelines Lower Urinary Tract Symptoms (LUTS) in men. NICE Clinical Guideline 97
More informationOPIOID PAIN MEDICATION Agreement and Informed Consent
OPIOID PAIN MEDICATION Agreement and Informed Consent I. Introduction Research and clinical experience show that opioid (narcotic) pain medications are helpful for some patients with chronic pain. The
More information18% Role of Pharmacist-Provided Medication Reviews in Workers Compensation Claims Management. Introduction. Role of the Pharmacist
Role of Pharmacist-Provided Medication Reviews in Workers Compensation Claims Management Benjamin Link, PharmD, RPh Introduction According to information from the National Council on Compensation Insurance
More informationGlossary of Clinical Trial Terms
Glossary of Clinical Trial Terms ADVERSE REACTION: (Adverse Event): Also known as side effects, adverse reactions include any undesired actions or effects of the experimental drug or treatment. Experimental
More informationUrostemol Men capsules THR 02855/0240
Urostemol Men capsules THR 02855/0240 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 14 Steps taken after initial registration Page 15 Summary of
More informationInvestigational Drugs: Investigational Drugs and Biologics
: I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place
More information